Company News

Orthocell has announced that Striate+™dental membrane has received regulatory approval under the new European Medical Device Regulations (MDR).

Orthocell was delighted to co-sponsor the inaugural Nerve Transfer and Reconstruction Symposium at the University of Western Australia last week.

This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth.

Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1,…

Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share. The report summarises…

Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory…

Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of…

Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued…

Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia. 

Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant…